In the last trading session, 0.11 million Gain Therapeutics Inc (NASDAQ:GANX) shares changed hands as the company’s beta touched 0.24. With the company’s per share price at $1.59 changed hands at $0.02 or 1.27% during last session, the market valuation stood at $42.44M. GANX’s last price was a discount, traded about -235.22% off its 52-week high of $5.33. The share price had its 52-week low at $0.89, which suggests the last value was 44.03% up since then. When we look at Gain Therapeutics Inc’s average trading volume, we note the 10-day average is 0.16 million shares, with the 3-month average coming to 308.93K.
Analysts gave the Gain Therapeutics Inc (GANX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 13 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended GANX as a Hold, 12 felt it is a Buy and 0 rated the stock as Underweight.
Gain Therapeutics Inc (NASDAQ:GANX) trade information
Instantly GANX was in green as seen at the end of in last trading. With action -4.76%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -50.99%, with the 5-day performance at -4.76% in the red. However, in the 30-day time frame, Gain Therapeutics Inc (NASDAQ:GANX) is -6.97% down. Looking at the short shares, we see there were 0.66 million shares sold at short interest cover period of 1.65 days.
The consensus price target for the stock as assigned by Wall Street analysts is 7, meaning bulls need an upside of 77.29% from its current market value. According to analyst projections, GANX’s forecast low is 4 with 10 as the target high. To hit the forecast high, the stock’s price needs a -528.93% plunge from its current level, while the stock would need to soar -151.57% for it to hit the projected low.
Gain Therapeutics Inc (GANX) estimates and forecasts
Data shows that the Gain Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 25.99% over the past 6 months, a 41.52% in annual growth rate that is considerably higher than the industry average of 16.40%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -79.01%. The 2024 estimates are for Gain Therapeutics Inc earnings to increase by 43.63%.
GANX Dividends
Gain Therapeutics Inc is expected to release its next quarterly earnings report in January.
Gain Therapeutics Inc (NASDAQ:GANX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 5.09% of Gain Therapeutics Inc shares while 7.96% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 8.39%. There are 7.96% institutions holding the Gain Therapeutics Inc stock share, with TIMELO INVESTMENT MANAGEMENT INC. the top institutional holder. As of 2024-06-30, the company held 3.3666% of the shares, roughly 0.61 million GANX shares worth $0.77 million.
DME CAPITAL MANAGEMENT, LP holds the second largest percentage of outstanding shares, with 3.1488% or 0.57 million shares worth $0.72 million as of 2024-06-30.
